Sarre S, Vandeneede D, Ebinger G, Michotte Y
Department of Pharmaceutical Chemistry and Drug Analysis, Vrije Universiteit Brussel, Brussels, Belgium.
J Neurochem. 1998 Apr;70(4):1730-9. doi: 10.1046/j.1471-4159.1998.70041730.x.
We investigated the effects of continuous intranigral perfusion of dopamine D1 and D2 receptor agonists and antagonists on the biotransformation of locally applied L-DOPA to dopamine in the substantia nigra of freely moving rats by means of in vivo microdialysis. The "dual-probe" mode was used to monitor simultaneously changes in extracellular dopamine levels in the substantia nigra and the ipsilateral striatum. Intranigral perfusion of 10 microM L-DOPA for 20 min induced a significant 180-fold increase in extracellular nigral dopamine level. No effect of the intranigral L-DOPA administration was observed on dopamine levels in the ipsilateral striatum, suggesting a tight control of extracellular dopamine in the striatum after enhanced nigral dopamine levels. Continuous nigral infusion with the D1 receptor agonist CY 208243 (10 microM) and with the D2 receptor agonist quinpirole at 10 microM (a nonselective concentration) attenuated the L-DOPA-induced increase in dopamine in the substantia nigra by 85 and 75%, respectively. However, perfusion of the substantia nigra with a lower concentration of quinpirole (1 microM) and the D1 antagonist SCH 23390 (10 microM) did not affect the nigral L-DOPA biotransformation. The D2 antagonist (-)-sulpiride (10 microM) also attenuated the L-DOPA-induced dopamine release in the substantia nigra to approximately 10% of that of the control experiments. We confirm that there is an important biotransformation of L-DOPA to dopamine in the substantia nigra. The high concentrations of dopamine formed after L-DOPA administration may be the cause of dyskinesias or further oxidative stress in Parkinson's disease. Simultaneous administration of D1 receptor agonists with L-DOPA attenuates the biotransformation of L-DOPA to dopamine in the substantia nigra. The observed effects could occur via changes in nigral GABA release that in turn influence the firing rate of the nigral dopaminergic neurons.
我们通过体内微透析研究了多巴胺D1和D2受体激动剂及拮抗剂持续脑内黑质灌注对自由活动大鼠黑质中局部应用的左旋多巴(L-DOPA)向多巴胺生物转化的影响。采用“双探针”模式同时监测黑质和同侧纹状体细胞外多巴胺水平的变化。脑内黑质灌注10微摩尔/升的L-DOPA 20分钟可使细胞外黑质多巴胺水平显著升高180倍。脑内给予L-DOPA对同侧纹状体多巴胺水平无影响,提示黑质多巴胺水平升高后纹状体细胞外多巴胺受到严格调控。持续向黑质输注D1受体激动剂CY 208243(10微摩尔/升)和D2受体激动剂喹吡罗(10微摩尔/升,非选择性浓度)分别使L-DOPA诱导的黑质多巴胺增加减少85%和75%。然而,用较低浓度的喹吡罗(1微摩尔/升)和D1拮抗剂SCH 23390(10微摩尔/升)灌注黑质并不影响黑质L-DOPA的生物转化。D2拮抗剂(-)-舒必利(10微摩尔/升)也使L-DOPA诱导的黑质多巴胺释放减少至对照实验的约10%。我们证实黑质中存在L-DOPA向多巴胺的重要生物转化。L-DOPA给药后形成的高浓度多巴胺可能是帕金森病中运动障碍或进一步氧化应激的原因。D1受体激动剂与L-DOPA同时给药可减弱黑质中L-DOPA向多巴胺的生物转化。观察到的效应可能通过黑质γ-氨基丁酸(GABA)释放的变化而发生,进而影响黑质多巴胺能神经元的放电频率。